Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: ASPERGILLOSIS - DRUG THERAPY , . Treffer: 19
2019
Cornely, OA; Hoenigl, M; Lass-Flörl, C; Chen, SC; Kontoyiannis, DP; Morrissey, CO; Thompson, GR; Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM)
Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology.
Mycoses. 2019; 62(9):716-729
Doi: 10.1111/myc.12960
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2018
Alastruey-Izquierdo, A; Cadranel, J; Flick, H; Godet, C; Hennequin, C; Hoenigl, M; Kosmidis, C; Lange, C; Munteanu, O; Page, I; Salzer, HJF; on behalf of CPAnet
Treatment of Chronic Pulmonary Aspergillosis: Current Standards and Future Perspectives.
Respiration. 2018; 96(2):159-170
Doi: 10.1159/000489474
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Jenks, JD; Salzer, HJ; Prattes, J; Krause, R; Buchheidt, D; Hoenigl, M
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Drug Des Devel Ther. 2018; 12(3):1033-1044
Doi: 10.2147/DDDT.S145545
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2017
Salzer, HJF; Lange, C; Hönigl, M
[Aspergillus in airway material : Ignore or treat?]
Internist (Berl). 2017; 58(11):1150-1162
Doi: 10.1007/s00108-017-0334-9
Web of Science
PubMed
FullText
FullText_MUG
2015
Dichtl, K; Samantaray, S; Aimanianda, V; Zhu, Z; Prévost, MC; Latgé, JP; Ebel, F; Wagener, J
Aspergillus fumigatus devoid of cell wall β-1,3-glucan is viable, massively sheds galactomannan and is killed by septum formation inhibitors.
Mol Microbiol. 2015; 95(3): 458-71.
Doi: 10.1111/mmi.12877
Web of Science
PubMed
FullText
FullText_MUG
Eigl, S; Prattes, J; Reinwald, M; Thornton, CR; Reischies, F; Spiess, B; Neumeister, P; Zollner-Schwetz, I; Raggam, RB; Flick, H; Buchheidt, D; Krause, R; Hoenigl, M
Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test.
Int J Antimicrob Agents. 2015; 46(4):401-405
Doi: 10.1016/j.ijantimicag.2015.05.017
Web of Science
PubMed
FullText
FullText_MUG
2013
Buzina, W
Aspergillus--classification and antifungal susceptibilities.
Curr Pharm Des. 2013; 19(20):3615-3628
Doi: 10.2174/1381612811319200005
Web of Science
PubMed
FullText
FullText_MUG
Hoenigl, M; Duettmann, W; Raggam, RB; Seeber, K; Troppan, K; Fruhwald, S; Prueller, F; Wagner, J; Valentin, T; Zollner-Schwetz, I; Wölfler, A; Krause, R
Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.
Antimicrob Agents Chemother. 2013; 57(7):3262-3267
Doi: 10.1128/AAC.00251-13
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Hoenigl, M; Krause, R
Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis.
Curr Pharm Des. 2013; 19(20):3648-3668
Doi: 10.2174/13816128113199990342
Web of Science
PubMed
FullText
FullText_MUG
Lichtenstern, C; Hochreiter, M; Zehnter, VD; Brenner, T; Hofer, S; Mieth, M; Büchler, MW; Martin, E; Weigand, MA; Schemmer, P; Busch, CJ
Pretransplant model for end stage liver disease score predicts posttransplant incidence of fungal infections after liver transplantation.
Mycoses. 2013; 56(3):350-357
Doi: 10.1111/myc.12041
Web of Science
PubMed
FullText
FullText_MUG
2012
Hoenigl, M; Raggam, RB; Salzer, HJ; Valentin, T; Valentin, A; Zollner-Schwetz, I; Strohmeier, AT; Seeber, K; Wölfler, A; Sill, H; Krause, R
Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies.
Int J Antimicrob Agents. 2012; 39(6):510-513
Doi: 10.1016/j.ijantimicag.2012.02.002
Web of Science
PubMed
FullText
FullText_MUG
2011
Traunmüller, F; Popovic, M; Konz, KH; Smolle-Jüttner, FM; Joukhadar, C
Efficacy and safety of current drug therapies for invasive aspergillosis.
Pharmacology. 2011; 88(3-4): 213-224.
Doi: 10.1159/000331860
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2010
Perkhofer, S; Lass-Flörl, C; Hell, M; Russ, G; Krause, R; Hönigl, M; Geltner, C; Auberger, J; Gastl, G; Mitterbauer, M; Willinger, B; Knöbl, P; Resch, G; Waldner, R; Makrai, A; Hartmann, G; Girschikofsky, M; Greil, R
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients.
Int J Antimicrob Agents. 2010; 36(6):531-536
Doi: 10.1016/j.ijantimicag.2010.08.010
Web of Science
PubMed
FullText
FullText_MUG
2009
Arendrup, MC; Garcia-Effron, G; Buzina, W; Mortensen, KL; Reiter, N; Lundin, C; Jensen, HE; Lass-Florl, C; Perlin, DS; Bruun, B
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
Antimicrob Agents Chemother. 2009; 53(3):1185-1193
Doi: 10.1128/AAC.01292-08
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2008
Auberger, J; Lass-Flörl, C; Clausen, J; Bellmann, R; Buzina, W; Gastl, G; Nachbaur, D
First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation.
Diagn Microbiol Infect Dis. 2008; 62(3):336-339
Doi: 10.1016/j.diagmicrobio.2008.06.012
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
2007
Staber, P; Langner, S; Dornbusch, HJ; Neumeister, P
Antifungal management in cancer patients.
Wien Med Wochenschr. 2007; 157(19-20):503-510
Doi: 10.1007/s10354-007-0466-y
PubMed
FullText
FullText_MUG
2000
Faschinger, CW
Phototherapeutic keratectomy of a corneal scar due to presumed infection after photorefractive keratectomy.
J Cataract Refract Surg. 2000; 26(2):296-300
Doi: 10.1016/S0886-3350(99)00337-5
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
1995
Dornbusch, HJ; Urban, CE; Pinter, H; Ginter, G; Fotter, R; Becker, H; Miorini, T; Berghold, C
Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases.
Pediatr Hematol Oncol. 1995; 12(6):577-586
Doi: 10.3109/08880019509030772
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
1992
Lackner, H; Schwinger, W; Urban, C; Müller, W; Ritschel, E; Reiterer, F; Kuttnig-Haim, M; Urlesberger, B; Hauer, C
Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight.
Pediatrics. 1992; 89(6 Pt 2):1259-1261
Doi: 10.1542/peds.89.6.1259
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar